Samaritan's Adult Stem Cell Drug Displays Money-Making Signs

Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer
of innovative drugs, announced today its Alzheimer's adult stem cell
drug SP-sc04, which induces dormant brain neuronal stem cells to
differentiate rapidly into adult neuron cells, is progressing through
preclinical studies with promising results.
   According to a CEO Magazine March 2006 article titled "Have Stem
Cells Arrived?" Fran Hawthorne stated, "signs point to an emerging,
money-making industry" and William R. Brody, president of Johns
Hopkins University, is quoted, "I don't think I have ever seen
anything that has the broad potential that stem cell technology has."
   "We are extremely pleased with the progress and the potential of
SP-04. Although it is early stage, each preclinical study we
accomplish gives us hope that we might have an extraordinary treatment
for the mind robbing disease of Alzheimer's," stated Dr. Greeson, CEO
of Samaritan.
   http://www.chiefexecutive.net/ME2/dirmod.asp?sid=&nm=&type=Publish
ing&mod=Publications%3A%3AArticle&mid=8F3A7027421841978F18BE895F87F791
&tier=4&id=A83BC9A72A074876BCA05E0ED18D56E2

   Samaritan Pharmaceuticals: "We LIV....to Save Lives."

   Samaritan is a small-cap biotech, driven to discover, develop and
commercialize, innovative therapeutics for AIDS, Alzheimer's, cancer
and heart disease. Look at www.samaritanpharma.com. Please register on
Web site so we can notify you of upcoming conference calls, news and
events.

   Disclaimer

   The company disclaims any information that is created by an
outside party, and endorses only information that is communicated by
its press releases, filings and Web site. This news release contains
forward-looking statements that reflect management's current beliefs
about the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development and
regulatory review. There are no guarantees that products will prove to
be commercially successful. For additional information about the
factors that affect the company's business, please read the company's
latest Form 10-K filed April 15, 2005. The company undertakes no duty
to update forward-looking statements.